| Today’s Big NewsMar 5, 2025 |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today! 
|
|
| By Gabrielle Masson Under President Donald Trump’s administration, the DOGE has reportedly terminated leases for at least 748 federal sites, including 30 FDA facilities across 23 states. |
|
|
|
By Kevin Dunleavy After Bayer's blood thinner Xarelto saw a sales decline of 600 million euros ($646 million) in 2024 because of generic competition, the company is projecting a sharper fall of between 1 billion and 1.5 billion euros in 2025. |
By Conor Hale While Shockwave's previous catheters emit sonic pressure waves around their circumference, the Javelin system is designed to deliver energy forward from its tip. |
By Gabrielle Masson Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. |
By Andrea Park After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out about its atopic dermatitis treatment Ebglyss. |
By Angus Liu Eli Lilly has established an online portal to accept submissions for possible locations of future U.S. manufacturing sites. |
By Conor Hale After selling its afib-focused startup to Boston Scientific earlier this year, Ajax Health and KKR are teaming up with the medtech for another new venture. |
By Zoey Becker The move follows a similar price cut by Eli Lilly as both GLP-1 drugmakers attempt to fend off cheaper compounded versions of their popular obesity meds. |
By Nick Paul Taylor Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline. |
By Nick Paul Taylor The FDA has sent its first untitled letter of 2025, hitting Edenbridge Pharmaceuticals with a notice after assessing the drugmaker's compliance with the rules on promoting prescription drugs in an exhibit booth panel. |
By Joseph Keenan CDMO CordenPharma plans to spend half of its €1 billion strategic peptide investment on a new production facility outside of Basel, Switzerland. The plant, which is slated to kick off commercial operations in the first half of 2028, will be able to tackle both GLP-1 and non-GLP-1 peptide projects, CordenPharma said. |
By Andrea Park A new survey commissioned by Leo Pharma confirms that there’s plenty of room in the market for its chronic hand eczema treatment Anzupgo, which is currently under review by the FDA. |
By James Waldron ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker. |
By Conor Hale While Shockwave's previous catheters emit sonic pressure waves around their circumference, the Javelin system is designed to deliver energy forward from its tip. |
By Dave Muoio The VA said its cuts are the “first step” in its audit of the roughly 90,000 contracts it currently has in place—a process its announcement stressed is being conducted with in-house expertise and feedback. Specific plans for the savings will be shared "in the coming weeks and months," the department said. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we hear from Steven McCarroll, Ph.D., whose research team at the Broad Institute of MIT and Harvard recently uncovered new insights into the cause of Huntington's disease. |
|
|---|
|
|
|
Wednesday, April 9, 2025 | 10am ET / 7am PTLearn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot! 
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Submissions Open Early August |
|
|
| |
|
+(1).png)
